Mohammed Rafii-El-Idrissi Benhnia

Mohammed Rafii-El-Idrissi Benhnia

Auto-generated profile, based on publicly available information

Mohammed Rafii-El-Idrissi Benhnia

Institute of Biomedicine of Seville, IBiS, UGC Clinical Laboratories, Virgen del Rocío University Hospital/CSIC/University of Seville

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
YKYuki Kinjo
Yuki Kinjo
ETEmmanuel Tupin
Emmanuel Tupin
DWDouglass Wu
Douglass Wu
MFMasakazu Fujio
Masakazu Fujio
RGRaquel Garcia-Navarro
Raquel Garcia-Navarro
MKMitchell Kronenberg
Mitchell Kronenberg

1 June 2008 in Immunity
Verified
Journal Article
Closed access
ASAlessandro Sette
Alessandro Sette
MMMagdalini Moutaftsi
Magdalini Moutaftsi
JMJuan Moyron-Quiroz
Juan Moyron-Quiroz
MMMegan M. McCausland
Megan M. McCausland
DDD. Huw Davies
D. Huw Davies
SCShane Crotty
Shane Crotty

1 February 2009 in Journal of Virology
Verified
Journal Article
Closed access
MBMohammed Rafii-El-Idrissi Benhnia
Mohammed Rafii-El-Idrissi Benhnia
MMMegan M. McCausland
Megan M. McCausland
JMJuan Moyron
Juan Moyron
JLJohn Laudenslager
John Laudenslager
SGSteven Granger
Steven Granger
SCShane Crotty
Shane Crotty
Antibody neutralization is an important component of protective immunity against vaccinia virus (VACV). Two distinct virion forms, mature virion and enveloped virion (MV and EV, respectively), possess separate functions and nonoverlapping immunological properties. In this study we examined the mechanics of EV neutralization, focusing on EV protein B5 (also called B5R). We show that neutralization of EV is predominantly complement dependent. From a panel of high-affinity anti-B5 monoclonal antibodies (MAbs), the only potent neutralizer in vitro (90% at 535 ng/ml) was an immunoglobulin G2a (IgG2a), and neutralization was complement mediated. This MAb was the most protective in vivo against lethal intranasal VACV challenge. Further studies demonstrated that in vivo depletion of complement caused a >50% loss of anti-B5 IgG2a protection, directly establishing the importance of complement for protection against the EV form. However, the mechanism of protection is not sterilizing immunity via elimination of the inoculum as the viral inoculum consisted of a purified MV form. The prevention of illness in vivo indicated rapid control of infection. We further demonstrate that antibody-mediated killing of VACV-infected cells expressing surface B5 is a second protective mechanism provided by complement-fixing anti-B5 IgG. Cell killing was very efficient, and this effector function was highly isotype specific. These results indicate that anti-B5 antibody-directed cell lysis via complement is a powerful mechanism for clearance of infected cells, keeping poxvirus-infected cells from being invisible to humoral immune responses. These findings highlight the importance of multiple mechanisms of antibody-mediated protection against VACV and point to key immunobiological differences between MVs and EVs that impact the outcome of infection.

1 April 2014 in Structure
Verified
Journal Article
Closed access
ISInbal Sela-Culang
Inbal Sela-Culang
MBMohammed Rafii-El-Idrissi Benhnia
Mohammed Rafii-El-Idrissi Benhnia
MMMichael H. Matho
Michael H. Matho
TKThomas Kaever
Thomas Kaever
MMMatt Maybeno
Matt Maybeno
BPBjoern Peters
Bjoern Peters

1 April 2008 in Journal of Virology
Verified
Journal Article
Closed access
MBMohammed Rafii-El-Idrissi Benhnia
Mohammed Rafii-El-Idrissi Benhnia
MMMegan M. McCausland
Megan M. McCausland
HSHua-Poo Su
Hua-Poo Su
KSKavita Singh
Kavita Singh
JHJulia Hoffmann
Julia Hoffmann
SCShane Crotty
Shane Crotty
The smallpox vaccine is widely considered the gold standard for human vaccines, yet the key antibody targets in humans remain unclear. We endeavored to identify a stereotypic, dominant, mature virion (MV) neutralizing antibody target in humans which could be used as a diagnostic serological marker of protective humoral immunity induced by the smallpox vaccine (vaccinia virus [VACV]). We have instead found that diversity is a defining characteristic of the human antibody response to the smallpox vaccine. We show that H3 is the most immunodominant VACV neutralizing antibody target, as determined by correlation analysis of immunoglobulin G (IgG) specificities to MV neutralizing antibody titers. It was determined that purified human anti-H3 IgG is sufficient for neutralization of VACV; however, depletion or blockade of anti-H3 antibodies revealed no significant reduction in neutralization activity, showing anti-H3 IgG is not required in vaccinated humans (or mice) for neutralization of MV. Comparable results were obtained for human (and mouse) anti-L1 IgG and even for anti-H3 and anti-L1 IgG in combination. In addition to H3 and L1, human antibody responses to D8, A27, D13, and A14 exhibited statistically significant correlations with virus neutralization. Altogether, these data indicate the smallpox vaccine succeeds in generating strong neutralizing antibody responses not by eliciting a stereotypic response to a single key antigen but instead by driving development of neutralizing antibodies to multiple viral proteins, resulting in a “safety net” of highly redundant neutralizing antibody responses, the specificities of which can vary from individual to individual. We propose that this is a fundamental attribute of the smallpox vaccine.

1 April 1995 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
JCJuan R. Calvo
Juan R. Calvo
MRMohammed Rafii‐Ei‐Ldrissi
Mohammed Rafii‐Ei‐Ldrissi
David PozoDavid Pozo
David Pozo
JGJuan M. Guerrero
Juan M. Guerrero